Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

Figure 1 DNA variation trend of CD19-CAR-T cell and CD22-CAR-T cell. Copy number of CD19-CAR-T cells and CD22-CAR-T cells DNA per μg genome in peripheral blood of the lymphoma patient at different times. CAR: Chimeric antigen receptor; DNA: Deoxyribonucleic acid.

Figure 2 Changes in lung, subcutaneous mass, and abdominal mass before and after chimeric antigen receptor T cell therapy. A: The patient developed multiple pulmonary nodules after disease progression detected by computed tomography. After treatment with chimeric antigen receptor T cell (CAR-T) and programmed cell death protein-1 inhibitor for 21 days, the absorption of pulmonary nodules decreased significantly; B: Changes in the subcutaneous mass before and after CAR-T cell therapy. The comparison of local mass size before and after CAR-T cell treatment in the 1^st mo and 3^rd mo; and C: Changes in the abdominal mass detected by positron emission tomography-computed tomography before and after CAR-T cell therapy. In early diagnosis of the disease, the maximum standardized uptake values were 22.40 and 15.60 in the abdomen and pelvis, respectively. 5 mo after the combination treatment, the maximum standardized uptake values in the abdomen and pelvis were 3.80 and 3.30, respectively.